Analysts say diabetes drug Lantus will continue to be lucrative

06/29/2005 | CNNMoney

Sanofi-Aventis' diabetes drug, Lantus, has been on the market since 2000 and achieved blockbuster status last year; analysts say despite the entrance into the market of two competing drugs, Lantus should have increasing sales over the next five years. One analyst says Lantus has done well because it is the only once-a-day long-acting analogue and that gives it an advantage over the competition. Novo Nordisk's Levemir and Byetta, from Eli Lilly and Amylin Pharmaceuticals, were approved earlier this year.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN